Resultados globales: 8 registros encontrados en 0.02 segundos.
Artículos, Encontrados 6 registros
Documentos de investigación, Encontrados 2 registros
Artículos Encontrados 6 registros  
1.
11 p, 3.4 MB Low-dose statin treatment increases prostate cancer aggressiveness / Caro-Maldonado, Alfredo (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Camacho, Laura (Biochemistry and Molecular Biology Department, University of the Basque Country, Bilbao, Spain) ; Zabala-Letona, Amaia (CIBERONC, Madrid, Spain) ; Torrano, Verónica (CIBERONC, Madrid, Spain) ; Fernández-Ruiz, Sonia (CIBERONC, Madrid, Spain) ; Zamacola-Bascaran, Kepa (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Arreal, Leire (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Valcárcel-Jiménez, Lorea (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Martín-Martín, Natalia (CIBERONC, Madrid, Spain) ; Flores, Juana M. (Department of Animal Medicine and Surgery, School of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain) ; Cortazar, Ana R. (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Zúñiga-García, Patricia (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Arruabarrena-Aristorena, Amaia (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Guillaumond, Fabienne (Université Aix-Marseille, Marseille, France) ; Cabrera, Diana (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ; Falcón-Perez, Juan M. (IKERBASQUE, Basque foundation for science, Bilbao, Spain) ; Aransay, Ana M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain) ; Gomez-Muñoz, Antonio (Biochemistry and Molecular Biology Department, University of the Basque Country, Bilbao, Spain) ; Olivan, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Carracedo, Arkaitz (IKERBASQUE, Basque foundation for science, Bilbao, Spain) ; Universitat Autònoma de Barcelona
Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. [...]
2017 - 10.18632/oncotarget.22217
Oncotarget, Vol. 9 (october 2017) , p. 1494-1504  
2.
16 p, 5.8 MB Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells / Cánovas, Verónica (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Puñal, Yolanda (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Maggio, Valentina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Redondo, Enric (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Marín, Mercedes (Laboratory of Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Medical Oncoloy Department, Hospital Clinic, Barcelona, Spain) ; Mellado, Begoña (Laboratory of Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Medical Oncoloy Department, Hospital Clinic, Barcelona, Spain) ; Olivan, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Lleonart, Matilde (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Planas, Jacques (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Paciucci, Rosanna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Metastatic prostate cancer is presently incurable. The oncogenic protein PTOV1, first described in prostate cancer, was reported as overexpressed and significantly correlated with poor survival in numerous tumors. [...]
2017 - 10.18632/oncotarget.19467
Oncotarget, Vol. 8 (july 2017) , p. 59165-59180  
3.
17 p, 5.0 MB Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer / Sequeiros, Tamara (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Rigau, Marina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Chiva, Cristina (Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain) ; Montes, Melania (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Garcia-Grau, Iolanda (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Garcia, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Diaz, Sherley (Hospital Universitari Vall d'Hebron) ; Celma, Ana (Hospital Universitari Vall d'Hebron) ; Bijnsdorp, Irene (Department of Urology, VU University Medical Center, Amsterdam, The Netherlands) ; Campos, Alex (Sanford-Burnham Medical Research Institute, La Jolla, California, USA) ; Di Mauro, Primiano (Sagetis-Biotech; Grup d'Enginyeria de Materials (GEMAT) Institut Químic de Sarrià, Barcelona, Spain) ; Borrós, Salvador (Sagetis-Biotech; Grup d'Enginyeria de Materials (GEMAT) Institut Químic de Sarrià, Barcelona, Spain) ; Reventós, Jaume (IDIBELL-Bellvitge Biomedical Research Institute, Barcelona, Spain) ; Doll, Andreas (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Paciucci, Rosanna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Pegtel, Michiel (Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands) ; de Torres, Inés (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Sabidó, Eduard (Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain) ; Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Olivan, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Rapid and reliable diagnosis of prostate cancer (PCa) is highly desirable as current used methods lack specificity. In addition, identification of PCa biomarkers that can classify patients into high- and low-risk groups for disease progression at early stage will improve treatment decision-making. [...]
2016 - 10.18632/oncotarget.13634
Oncotarget, Vol. 8 (november 2016) , p. 4960-4976  
4.
60 p, 3.6 MB Biological properties of extracellular vesicles and their physiological functions / Yáñez-Mó, María (Universidad Autónoma de Madrid. Departamento de Biología Molecular) ; Siljander, Pia R.-M. (University of Helsinki. Department of Biosciences) ; Andreu, Zoraida (Universidad Autónoma de Madrid. Departamento de Biología Molecular) ; Zavec, Apolonija Bedina (National Institute of Chemistry (Ljubljana)) ; Borràs, Francesc E. (Institut Germans Trias i Pujol) ; Buzas, Edit I. (Semmelweis University. Department of Genetics, Cell- and Immunobiology) ; Buzas, Krisztina (University of Szeged. Faculty of Dentistry) ; Casal, Enriqueta (CIC bioGUNE) ; Cappello, Francesco (Euro-Mediterranean Institute of Science and Technology (Palermo)) ; Carvalho, Joana (Institute of Molecular Pathology and Immunology of the University of Porto) ; Colás, Eva (Vall d'Hebron Institut de Recerca) ; Cordeiro da Silva, Anabela (University of Porto. Department of Biological Sciences,) ; Fais, Stefano (National Institute of Health. Department of Therapeutic Research and Medicines Evaluation (Rome)) ; Falcón Pérez, Juan M. (CIC bioGUNE) ; Ghobrial, Irene M. (Dana-Farber Cancer Institute) ; Giebel, Bernd (University Hospital Essen. Institute for Transfusion Medicine) ; Gimona, Mario (Universitätsklinikum. Department of Blood Group Serology and Transfusion Medicine (Salzburg)) ; Graner, Michael (University of Colorado Denver. Department of Neurosurgery) ; Gursel, Ihsan (Bilkent University. Department of Molecular Biology and Genetics) ; Gursel, Mayda (Middle East Technical University. Department of Biological Sciences) ; Heegaard, Niels H. H. (Statens Serum Institut. Department of Clinical Biochemistry, Immunology & Genetics) ; Hendrix, An (Ghent University Hospital. Department of Radiation Oncology and Experimental Cancer Research) ; Kierulf, Peter (Oslo University Hospital. Department of Medical Biochemistry) ; Kokubun, Katsutoshi (Dana-Farber Cancer Institute) ; Kosanovic, Maja (University of Belgrade. Institute for the Application of Nuclear Energy) ; Kralj-Iglic, Veronika (University of Ljubljana. Faculty of Health Sciences) ; Krämer-Albers, Eva-Maria (University of Mainz. Molecular Cell Biology and Focus Program Translational Neurosciences) ; Laitinen, Saara (Finnish Red Cross Blood Service) ; Lässer, Cecilia (University of Gothenburg. Institute of Medicine at the Sahlgrenska Academy) ; Lener, Thomas (Universitätsklinikum. Department of Blood Group Serology and Transfusion Medicine) ; Ligeti, Erzsébet (Semmelweis University. Department of Physiology) ; Linē, Aija (Latvian Biomedical Research and Study Centre) ; Lipps, Georg (University of Applied Sciences and Arts Northwestern Switzerland. Institute of Chemistry and Bioanalytics) ; Llorente, Alicia (Oslo University Hospital - The Norwegian Radium Hospital. Institute for Cancer Research) ; Lötvall, Jan (University of Gothenburg. Institute of Medicine at the Sahlgrenska Academy) ; Manček-Keber, Mateja (EN→FIST Centre of Excellence (Ljubljana)) ; Marcilla, Antonio (Universitat de Valencia. Departamento de Biología Celular y Parasitologia) ; Mittelbrunn, Maria (Centro Nacional de Investigaciones Cardiovasculares (Madrid)) ; Nazarenko, Irina (University of Freiburg. Institute for Environmental Health Sciences and Hospital Infection Control Medical Center) ; Nolte-'t Hoen, Esther N.M. (Utrecht University. Department of Biochemistry and Cell Biology) ; Nyman, Tuula A. (University of Helsinki. Institute of Biotechnology) ; O'Driscoll, Lorraine (Trinity College Dublin. School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute) ; Olivan, Mireia (Vall d'Hebron Institut de Recerca) ; Oliveira, Carla (University of Porto. Department of Pathology and Oncology) ; Pállinger, Éva (Semmelweis University. Department of Genetics, Cell- and Immunobiology) ; del Portillo, Hernando A. (Institució Catalana de Recerca i Estudis Avançats) ; Reventós, Jaume (Vall d'Hebron Institut de Recerca) ; Rigau, Marina (Vall d'Hebron Institut de Recerca) ; Rohde, Eva (Universitätsklinikum. Department of Blood Group Serology and Transfusion Medicine (Salzburg)) ; Sammar, Marei (ORT Braude College. Department of Biotechnology Engineering) ; Sánchez-Madrid, Francisco (Hospital de la Princesa. Instituto de Investigaciones Sanitarias Princesa) ; Santarém, N. (IBMC - Instituto de Biologia Molecular e Celular, Universidade do Porto) ; Schallmoser, Katharina (Uniklinikum Salzburg. University Clinic of Blood Group Serology and Transfusion Medicine) ; Ostenfeld, Marie Stampe (Aarhus University Hospital. Departmnet of Molecular Medicine) ; Stoorvogel, Willem (Utrecht University. Department of Biochemistry and Cell Biology) ; Stukelj, Roman (University of Ljubljana. Laboratory of Clinical Biophysics) ; Van der Grein, Susanne G. (Utrecht University. Department of Biochemistry and Cell Biology) ; Vasconcelos, M. Helena (University of Porto. Department of Biological Sciences) ; Wauben, Marca H. M. (Utrecht University. Department of Biochemistry and Cell Biology) ; De Wever, Olivier (Ghent University Hospital. Department of Radiation Oncology and Experimental Cancer Research) ; Universitat Autònoma de Barcelona
In the past decade, extracellular vesicles (EVs) have been recognized as potent vehicles of intercellular communication, both in prokaryotes and eukaryotes. This is due to their capacity to transfer proteins, lipids and nucleic acids, thereby influencing various physiological and pathological functions of both recipient and parent cells. [...]
2015 - 10.3402/jev.v4.27066
Journal of extracellular vesicles, Vol. 4 (2015)  
5.
9 p, 695.8 KB Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness / Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Celma, Anna (Hospital de la Vall Hebron. Departament d'Urologia) ; Planas, Jacques (Hospital de la Vall Hebron. Departament d'Urologia) ; Placer, José (Hospital de la Vall Hebron. Departament d'Urologia) ; de Torres, Inés (Hospital de la Vall Hebron. Departament de Patologia) ; Olivan, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Carles, Juan (Universitat Internacional de Catalunya. Department de Ciències Bàsiques) ; Reventós, Jaume (IDIBELL-Institut d'Investigació Biomèdica de Bellvitge) ; Doll, Andreas (DUniversitat Internacional de Catalunya. Department de Ciències Bàsiques)
The aim of this study was to analyze the relationship between statin use along with serum cholesterol levels and prostate cancer (PCa) detection and aggressiveness. Statin users of three years or more and serum cholesterol levels (SC) were assessed in 2408 men scheduled for prostate biopsy. [...]
2014 - 10.3390/ijms150813615
International journal of molecular sciences, Vol. 15 (august 2014) , p. 13615-13623  
6.
30 p, 2.0 MB The Present and Future of Prostate Cancer Urine Biomarkers / Rigau, Marina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Olivan, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Garcia, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Sequeiros, Tamara (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Montes, Melania (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Colás, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Llauradó, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Planas, Jacques (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; de Torres, Inés (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Morote Robles, Juan (Universitat Autònoma de Barcelona. Departament de Cirurgia) ; Cooper, Colin (Cancer Genetics, University of East Anglia, Norwich Norfolk, NR4 7TJ, UK; E-Mails: (C.C.); (J.C.)) ; Reventós, Jaume (Department of Basic Sciences, International University of Catalonia, 08017 Barcelona, Spain) ; Clark, Jeremy (Cancer Genetics, University of East Anglia, Norwich Norfolk, NR4 7TJ, UK; E-Mails: (C.C.); (J.C.)) ; Doll, Andreas (Hospital Universitari Vall d'Hebron. Institut de Recerca)
In order to successfully cure patients with prostate cancer (PCa), it is important to detect the disease at an early stage. The existing clinical biomarkers for PCa are not ideal, since they cannot specifically differentiate between those patients who should be treated immediately and those who should avoid over-treatment. [...]
2013 - 10.3390/ijms140612620
International journal of molecular sciences, Vol. 14 (june 2013) , p. 12620-12649  

Documentos de investigación Encontrados 2 registros  
1.
179 p, 3.3 MB MicroRNAs as predictors and therapy for prostate cancer / Montes Pérez, Melania ; Reventós i Puigjaner, Jaume, dir ; Morote Robles, Juan, dir ; Olivan Riera, Mireia, dir ; Universitat Autònoma de Barcelona. Departament de Medicina
Prostate cancer (PC) is the most common neoplasia among males from developed countries and the second leading cause of death from cancer in these males. During the last years, serum prostate specific antigen (PSA) has been used as biomarker for PC diagnosis. [...]
Bellaterra : Universitat Autònoma de Barcelona, 2015  
2.
85 p, 795.5 KB Craniectomía descompresiva frente la hipertensión intracraneal / Anglada Olivan, Mireia ; Balibrea del Castillo, José María ; Marcos Neira, Pilar ; Universitat Autònoma de Barcelona. Departament de Cirurgia ; Universitat Autònoma de Barcelona. Facultat de Medicina
La craniectomia descompressiva es presenta com una estratègia terapèutica davant la hipertensió intracranial refractària al tractament mèdic. L'objectiu és avaluar els efectes de la CD en el resultat funcional dels pacients en els quals les mesures terapèutiques convencionals no aconsegueixen un control òptim de la pressió intracranial. [...]
La craniectomía descompresiva se presenta como estrategia terapéutica frente la hipertensión intracraneal refractaria al tratamiento médico. El objetivo es evaluar los efectos de la CD sobre el resultado funcional de los pacientes en los que las medidas terapéuticas convencionales no logran el control óptimo de la presión intracraneal. [...]

2011  

Vea también: autores con nombres similares
2 Olivan, M.
1 Oliván, M.J.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.